Nodenza Venture Partners to attend BioFuture NYC 2025
- Article
- Oct 8, 2025
- 1 Min Read
Written By Nodenza
New York, NY – October 13-15, 2025 – Nodenza Venture Partners (“Nodenza”) will attend BioFuture in New York City.
The firm will engage with biotechnology, digital health, and medtech companies aligned with its investment strategy spanning early clinical development (IND through Phase 2) and product launch assets transitioning toward commercialization.
Nodenza will also meet with institutional investors and strategic partners during the conference’s partnering program.
Event Information: BioFuture NYC
Contacts
Nodenza Venture Partner
Notes For Editors
About Nodenza Venture Partners
Nodenza Venture Partners provides investment and operational support to clinical proof-of-concept and product launch biotech and medtech companies seeking to bring exceptional benefits to patients. Our bi-modal investment strategy combines early-stage opportunities – advancing new treatment modalities through active IND to phase 2 – with commercial targets supporting their transition from scientific to commercial companies delivering strong upside potential. Established by a team of experienced life sciences entrepreneurs, founders and leaders, our approach leverages Nodenza’s extensive expertise in the creation and growth of new companies, as well as late-stage product development and launch.
